衣原体候选疫苗CTH522联合CAF01或氢氧化铝佐剂的首个人体随机双盲安慰剂对照1期试验的安全性与免疫原性
该1期首次人体试验在健康女性中评估重组蛋白亚单位衣原体疫苗CTH522分别联合CAF01脂质体或氢氧化铝佐剂的安全性与免疫原性。结果显示两种疫苗均安全耐受,且均诱导100%抗CTH522 IgG血清阳转,其中CTH522:CAF01免疫原性更优。
要点
- 两种佐剂疫苗均安全耐受,最常见为轻度局部注射部位反应。
- 5次免疫后CTH522:CAF01和CTH522:AH组均100%抗CTH522 IgG血清阳转。
- CTH522:CAF01较CTH522:AH血清阳转加速、IgG滴度更高、黏膜抗体谱增强。
核心结论
- CTH522联合CAF01或氢氧化铝佐剂均安全耐受且具免疫原性,CTH522:CAF01免疫原性更优,值得进一步临床开发。
研究设计与样本
- 1期首次人体随机双盲平行安慰剂对照试验,在伦敦Hammersmith医院纳入19-45岁健康女性,按3:3:1随机分组。
- 35名女性随机接受CTH522:CAF01(15例)、CTH522:AH(15例)或安慰剂(5例)。
主要发现
- 5次免疫后CTH522:CAF01和CTH522:AH组抗CTH522 IgG血清阳转均为15/15(100%),安慰剂组无阳转。
- CTH522:CAF01较CTH522:AH血清阳转加速、IgG滴度升高、黏膜抗体谱增强、细胞免疫应答更一致。
关键数值与推荐
- 主要结局为安全性,次要结局为抗CTH522 IgG血清阳转。
- 32名(91%)完成全部5次接种,所有参与者纳入意向性分析。
临床怎么用
- 提示CTH522:CAF01作为衣原体疫苗候选值得进一步临床开发。
- 当前数据来自1期小样本健康女性,尚不能用于临床接种决策。
局限性
- 1期首次人体试验样本量小(35例),仅纳入健康女性。
- 随访与免疫原性数据限于5次免疫后的短期评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chlamydia is the most common sexually transmitted bacterial infection worldwide. National screening programmes and antibiotic treatment have failed to decrease incidence, and to date no vaccines against genital chlamydia have been tested in clinical trials. We aimed to assess the safety and immunogenicity, in humans, of a novel chlamydia vaccine based on a recombinant protein subunit (CTH522) in a prime-boost immunisation schedule. METHODS: This phase 1, first-in-human, double-blind, parallel, randomised, placebo-controlled trial was done at Hammersmith Hospital in London, UK, in healthy women aged 19-45 years. Participants were randomly assigned (3:3:1) to three groups: CTH522 adjuvanted with CAF01 liposomes (CTH522:CAF01), CTH522 adjuvanted with aluminium hydroxide (CTH522:AH), or placebo (saline). Participants received three intramuscular injections of 85 μg vaccine (with adjuvant) or placebo to the deltoid region of the arm at 0, 1, and 4 months, followed by two intranasal administrations of 30 μg unadjuvanted vaccine or placebo (one in each nostril) at months 4·5 and 5·0. The primary outcome was safety and the secondary outcome was humoral immunogenicity (anti-CTH522 IgG seroconversion). This study is registered with Clinicaltrials.gov, number NCT02787109. FINDINGS: Between Aug 15, 2016, and Feb 13, 2017, 35 women were randomly assigned (15 to CTH522:CAF01, 15 to CTH522:AH, and five to placebo). 32 (91%) received all five vaccinations and all participants were included in the intention-to-treat analyses. No related serious adverse reactions were reported, and the most frequent adverse events were mild local injection-site reactions, which were reported in all (15 [100%] of 15) participants in the two vaccine groups and in three (60%) of five participants in the placebo group (p=0·0526 for both comparisons). Intranasal vaccination was not associated with a higher frequency of related local reactions (reported in seven [47%] of 15 participants in the active treatment groups vs three [60%] of five in the placebo group; p=1·000). Both CTH522:CAF01 and CTH522:AH induced anti-CTH522 IgG seroconversion in 15 (100%) of 15 participants after five immunisations, whereas no participants in the placebo group seroconverted. CTH522:CAF01 showed accelerated seroconversion, increased IgG titres, an enhanced mucosal antibody profile, and a more consistent cell-mediated immune response profile compared with CTH522:AH. INTERPRETATION: CTH522 adjuvanted with either CAF01 or aluminium hydroxide appears to be safe and well tolerated. Both vaccines were immunogenic, although CTH522:CAF01 had a better immunogenicity profile, holding promise for further clinical development. FUNDING: European Commission and The Innovation Fund Denmark.
引用
- Abraham S, Juel HB, Bang P, et al. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2019. PMID: 31416692. doi:10.1016/S1473-3099(19)30279-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。